News

September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).

Home September 03, 2009
Home
News

September 2, 2009 – Edwards Lifesciences Corp. said this week it completed enrollment in its 1,040-patient randomized controlled investigational device exemption (IDE) study of the Edwards SAPIEN transcatheter heart valve.

Home September 03, 2009
Home
News

September 3, 2009 – Boston Scientific Corp. said Tuesday long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II) found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality when implanted in patients following myocardial infarction.

Home September 03, 2009
Home
News

September 3, 2009 – The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday at the European Society of Cardiology Congress in Barcelona, which did not show a statistical difference between the high-dose and standard-dose PLAVIX regimens, but subgroups did show some improvement.

Home September 03, 2009
Home
News

September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.

Home September 02, 2009
Home
News

September 2, 2009 – Volcano Corp. said this week it entered into a nonexclusive, global resale agreement with Siemens Healthcare where Siemens will resell Volcano’s s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems.

Home September 02, 2009
Home
Technology

September 2, 2009 – A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39 percent, compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevat

Home September 02, 2009
Home
News

September 1, 2009 - Evaluation of results of a multicenter study indicates that quantitative evaluation of the progression of volume of extracranial carotid vessel walls is feasible with 1.5T magnetic resonance (MR) imaging, despite limitations due to patient motion or habitus.

Home September 01, 2009
Home
News

September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER sirolimus-eluting coronary stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, Ark.

Home September 01, 2009
Home
News

September 1, 2009 – St. Jude Medical Inc. today announced European launch of the next generation version 4.0 of its Merlin.net Patient Care Network (PCN), a secure, Internet-based remote care system for patients with implanted medical devices.

Home September 01, 2009
Home
News

September 1, 2009 – Sanofi-aventis said Sunday the investigational anti-Xa intravenous anti-coagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in four out of the five otamixaban tested doses, versus standard UFH/eptifibatide combination in (non-ST) ACS patients suitable for

Home September 01, 2009
Home
News

September 1, 2009 - BioClinica Inc., a clinical trial services provider, today announced that it has acquired the CardioNow unit of Agfa HealthCare to offer streamlined electronic transport solutions to facilitate the blinding, sharing, tracking and archiving of medical images for multi-center clinical trials as part of its suite of imaging services.

Home September 01, 2009
Home
Feature

September 1, 2009 – AstraZeneca last week announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (BRILINTA) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events (CV death, MI, stroke) over clopidogrel (Plavix/Iscover ) (9.8 vs.

Home September 01, 2009
Home
News

September 1, 2009 – Toshiba America Medical Systems Inc. will demonstrate its Next Generation Advanced Image Processing (AIP) feature, available on the Infinix-i product line at this year’s Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium.

Home September 01, 2009
Home
News

September 1, 2009 – Echocardiography with Doppler is the method of choice for the noninvasive evaluation of prosthetic valves, according to a new guideline document in the September issue of the Journal of the American Society of Echocardiography (JASE).

Home September 01, 2009
Home
Subscribe Now